To study thyroid hormone (TH) signaling in the human brain, we analyzed published microarray data sets of the temporal pole (Brodmann area 38) of 19 deceased donors. An index of TH signaling built on the expression of 19 well known TH-responsive genes in mouse brains (T3S+) varied from 0.92 to 1.1. After Factor analysis, T3S+ correlated independently with the expression of TH transporters (MCT8, LAT2), TH receptor (TR) beta and TR coregulators (CARM1, MED1, KAT2B,...

We developed an application (https://rush-covid19.herokuapp.com/) to aid US hospitals in planning their response to the ongoing COVID-19 pandemic. Our application forecasts hospital visits, admits, discharges, and needs for hospital beds, ventilators, and personal protective equipment by coupling COVID-19 predictions to models of time lags, patient carry-over, and length-of-stay. Users can choose from seven COVID-19 models, customize a large set of parameters, examine trends in testing and hospitalization, and download forecast data. The data and scripts...

Objective To quantify the impact of a healthy lifestyle on the risk of Alzheimer's dementia. Methods Using data from the Chicago Health and Aging Project (CHAP n=1,845) and the Rush Memory and Aging Project (MAP n=920), we defined a healthy lifestyle score on the basis of non-smoking, >=150 min/week moderate/vigorous intensity physical activity, light-to-moderate alcohol consumption, high-quality MIND diet (upper 40%), and engagement in late-life cognitive activities (upper 40%), giving an overall score ranging from...

Objective: To evaluate safety and tolerability and exploratory efficacy endpoints for gaboxadol (OV101) compared with placebo in individuals with Angelman syndrome (AS). Methods: Gaboxadol is a highly selective orthosteric agonist that activates γ-subunit–containing extrasynaptic γ-aminobutyric acid type A (GABAA) receptors. In a multicenter, double-blind, placebo-controlled, parallel-group trial, adolescent and adult individuals with a molecular diagnosis of AS were randomized (1:1:1) to 1 of 3 dosing regimens for a duration of 12 weeks: placebo morning dose...

Context: The Thr92Ala-DIO2 polymorphism may affect hypothyroid patients’ responses to levothyroxine (LT4) treatment. Objective: To study whether the Thr92Ala-DIO2 polymorphism affects hypothyroid patients’ responses to levothyroxine (LT4) treatment. Design: Secondary analysis of a randomized intervention study. Setting: Primary care center. Patients or Other Participants: 109 hypothyroid women aged 21-70 years with normal TSH levels grouped in homozygous Thr92-DIO2 (THR; n=39) and homozygous Ala92-DIO2 plus heterozygous (ALA; n=70) groups. Intervention: Change in LT4 dose. Main Outcome...